Deerfield backs $81M round for biotech developing antifungal therapy with less toxicity
Elion Therapeutics, a biotech focused on invasive fungal infections, has raised $81 million in a Series B funding round for its early-stage candidate, it announced …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.